However, due to resource constraints, our study only considered testing for the two most common EGFR mutations (Exon 19 deletion and Exon 21 L858R) in our cohort of patients with primary lung cancers, which was a limitation of our study. The gene discussed is EGFR; the disease is lung carcinoma.